Biogen swoops to appoint Ex-Roche Vice President
Biogen have appointed Anirvan Ghosh to the position of Senior Vice President of research and Early Development. Ghosh is slated to begin his role in April, leaving his current position of Chief Scientific Officer at E-Scape Bio, a biotech company focusing on therapies for Alzheimer’s disease.
Prior to this role, he held the position of Vice President, Global Head of Neuroscience Discovery and Biomarkers at Roche. In this role, he focused on research and drug discovery for neurodegenerative diseases and it is this expertise that has attracted Biogen to making this appointment.
“We are excited to have Anirvan Ghosh join us at Biogen,” said Dr Ehlers, Executive Vice President, Head of Research and Development. “After an extensive global search, we have found an inspired leader to guide an exceptional Research and Early Development team. Anirvan is an accomplished neuroscientist and industry R&D leader who has delivered multiple novel drug candidates to the clinic.”
Commenting on his own reasons for joining the company, Dr Ghosh said, “Biogen has been a pioneer in bringing breakthrough medicines to patients with multiple sclerosis and spinal muscular atrophy, as well as finding new approaches for Alzheimer’s disease, Parkinson’s disease, and ALS – conditions that represent some of the hardest challenges in medicine. I am excited and honoured to lead Research and Early Development, and I look forward to accelerating our efforts to translate the highest quality science and our best ideas into a new generation of medicines at Biogen.”
- NICE reverses decision on medication for relapsing multiple sclerosis
- UK High Court rules against AbbVie’s Humira patents
- Biogen shells out $1.25bn to protect best-selling MS drug
- Biogen’s gains late-year drug approval first for controversially expensive drug
- Neurodegenerative market to be worth $45 billion by 2022